title: [Androgen receptors in breast cancer: Expression, value and therapeutic prospects].
abstract: Triple-negative (TN) breast cancer are characterized by lack of estrogen receptor (OR) and progesterone receptor (PR) expression, and the absence of overexpression of human epidermal growth factor receptor 2 (HER2). It is a heterogeneous group of tumors with a more pejorative prognosis than other subtypes of breast cancer. Androgen receptors (AR) are nuclear receptors whose expression varies from 80 to 85% of primary breast cancers and 60 to 75% of metastatic cancers. Among the TN breast cancers, the luminal androgen receptor (LAR) subtype expresses AR more frequently, up to 53% of the cases. AR are associated with lower tumor size, histological grade, Ki67, and lymph node involvement. The results of recent clinical trials evaluating anti-androgen therapies in locally advanced or metastatic TN breast cancer are promising. Many new therapies are tested, including enzalutamide or abiraterone acetate, and numerous therapeutic combinations including PI3K/AKT/mTOR inhibitors or CDK inhibitors. These therapies would allow an alternative treatment of patients with TN breast cancer for which there is often a therapeutic impasse.
authors.affiliation: Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 138673 Singapour, Singapour; Centre René-Huguenin, institut Curie, département de chirurgie oncologique, 35, rue Dailly, 92210 Saint-Cloud, France. Electronic address: delphine.hequet@gmail.com.
authors.forename: Delphine
authors.initials: D
authors.lastname: Héquet
authors.affiliation: Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 138673 Singapour, Singapour.
authors.forename: Slim
authors.initials: S
authors.lastname: Mzoughi
authors.affiliation: Centre René-Huguenin, institut Curie, département de chirurgie oncologique, 35, rue Dailly, 92210 Saint-Cloud, France; Université Versailles-St-Quentin-en-Yvelines, EA 7285 : risques cliniques et sécurité en santé des femmes et en santé périnatale, 2, rue de la Source-de-la-Bièvre, 78180 Montigny-le-Bretonneux, France.
authors.forename: Roman
authors.initials: R
authors.lastname: Rouzier
authors.affiliation: Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 138673 Singapour, Singapour.
authors.forename: Ernesto
authors.initials: E
authors.lastname: Guccione
mesh_terms: D000069501:Abiraterone Acetate / Q000627:therapeutic use; D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D051358:Cyclin-Dependent Kinase 4 / Q000037:antagonists & inhibitors; D051361:Cyclin-Dependent Kinase 6 / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D008207:Lymphatic Metastasis; D009363:Neoplasm Proteins / Q000378:metabolism*; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011379:Prognosis; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D011944:Receptors, Androgen / Q000737:chemistry / Q000378:metabolism*; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D047368:Tumor Burden
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D001549:Benzamides; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D009570:Nitriles; D061026:Programmed Cell Death 1 Receptor; D011944:Receptors, Androgen; D010669:Phenylthiohydantoin; C540278:enzalutamide; D013254:Steroid 17-alpha-Hydroxylase; D058570:TOR Serine-Threonine Kinases; C495900:CDK4 protein, human; C495911:CDK6 protein, human; D051358:Cyclin-Dependent Kinase 4; D051361:Cyclin-Dependent Kinase 6; D000069501:Abiraterone Acetate
keywords: Androgen receptors; Breast cancer; Cancer du sein; Récepteurs aux androgènes